Osteoporosis Drugs Global Market Report 2024

The osteoporosis drugs market size has grown steadily in recent years. It will grow from $12 billion in 2023 to $12.48 billion in 2024 at a compound annual growth rate (CAGR) of 4.0%. The growth observed in the historical period can be attributed to an aging population, heightened awareness and diagnosis, lifestyle factors, and government initiatives and healthcare policies.

The osteoporosis drugs market size is expected to see steady growth in the next few years. It will grow to $14.2 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%. The forecasted growth is driven by continuing trends of an aging population, advancements in treatment options, increased focus on men's bone health, patient education, and global health policies. Key trends include personalized medicine, exploration of combination therapies, emphasis on fracture prevention, research and development in novel drug targets, and collaborative efforts for drug development.

The increasing prevalence of osteoporosis is anticipated to drive the growth of the osteoporosis drug market. Osteoporosis, a bone disease characterized by a decline in bone mineral density and mass or changes in bone quality and structure, is often associated with low calcium intake. Osteoporosis drugs play a crucial role in increasing bone mineral density and preventing fractures in individuals affected by the condition. For example, as of May 2022, statistics from Amgen, a US-based biotechnology company, revealed that osteoporosis causes approximately 1.5 million fractures in the United States annually, resulting in associated costs amounting to $19 billion. Furthermore, the annual number of fractures caused by osteoporosis is projected to increase by 68% from 2018 to 2040, rising from 1.9 million to 3.2 million. Consequently, the surging prevalence of osteoporosis stands as a key factor driving the growth of the osteoporosis drug market.

The rising aging population is anticipated to be a significant driver for the growth of the osteoporosis drug market in the foreseeable future. The aging population refers to an increase in the median age of a population, primarily influenced by declining fertility rates and prolonged life expectancy. Osteoporosis risk is known to escalate with age due to the natural decline in bone density. The expanding demographic of elderly individuals contributes to a growing demand for osteoporosis medications. For example, in 2022, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that the global population aged 60 years and over increased from 1 billion to 1.4 billion. Projections for 2050 anticipate a doubling of the world's population of individuals aged 60 years and older to reach 2.1 billion. Hence, the increasing aging population emerges as a key factor driving the growth of the osteoporosis drug market.

Key players in the osteoporosis drugs industry are driving forward with innovative approaches to address this market. An example of this progress is seen in Apotex Inc., a Canadian pharmaceutical giant, which introduced the Teriparatide Injectable for Osteoporosis Treatment in November 2023. This pre-filled pen, containing 250 mcg/mL, facilitates 28 daily doses of 20 mcg each, specifically designed for single-patient usage. This offering aims to provide affordable access to much-needed treatment for patients dealing with osteoporosis.

Major players in the osteoporosis drug market are strategically leveraging partnerships to ensure dependable services for their clientele. A case in point is the December 2022 collaboration between Chugai Pharmaceutical Co. Ltd., a Japanese pharmaceutical company, and Towa Pharmaceutical Co. Ltd., a Japan-based manufacturer specializing in generic drug development. This alliance facilitated the introduction of Edirol Tablet for osteoporosis treatment. Chugai's production of Edirol tablets, supplied to Towa, showcases this active vitamin D3 derivative's efficacy in enhancing calcium and bone metabolism. This joint effort significantly contributes to diversifying treatment options available in the osteoporosis drug market, addressing the needs of individuals dealing with this condition.

In August 2021, Nestlé Health Science, a Switzerland-based provider of nutrition solutions, diagnostics, devices, and drugs, successfully acquired the core brands of Bountiful Company for an undisclosed amount. This strategic acquisition is aimed at enhancing Nestlé Health Science's portfolio with trusted products and methodologies, further advancing its mission to improve the health of clients globally. Bountiful Company, based in the United States, is recognized for its joint care supplement brand.

Major companies operating in the osteoporosis drugs market report are Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Pharma Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Union Chimique Belge, Sun Pharmaceutical Industries Ltd., Ipsen, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Recordati S.p.A., Cadila Healthcare Ltd., Lupin Limited, Enzene Biosciences Ltd., Torrent Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Ligand Pharmaceuticals Incorporated, Theramex, Radius Health Inc., Actavis PLC, Strides Pharma Science Limited, Apotex Inc.

North America was the largest region in the osteoporosis market in 2023. The regions covered in the osteoporosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the osteoporosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of osteoporosis drugs comprise bisphosphonates, selective estrogen receptor modulators (SERMS), and rank ligand inhibitors. Bisphosphonates are a class of medications aimed at addressing bone conditions such as osteopenia or osteoporosis, both characterized by fragile or thin bones susceptible to fractures. These drugs are available in oral and intravenous forms, distributed through diverse channels such as retail pharmacies, hospital dispensaries, and online sales platforms. They find application in treating both primary and secondary osteoporosis.

The osteoporosis drugs market research report is one of a series of new reports that provides osteoporosis drugs market statistics, including osteoporosis drugs industry global market size, regional shares, competitors with a osteoporosis drugs market share, detailed osteoporosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis drugs industry. This osteoporosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The osteoporosis drugs market consists of sales of antiresorptive drugs and anabolic drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.